SPOTLIGHT -
Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment
Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.
Read More
Dr. Paul on the Management of CRS and ICANS After CAR T-cell Therapy in Cancer Care
Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.
Dr. Paul on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma
Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
